{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:33:51Z","timestamp":1791498831075,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ebiom.2024.105544","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T07:34:27Z","timestamp":1736062467000},"page":"105544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth"],"prefix":"10.1016","volume":"112","author":[{"given":"Katrina M.","family":"Pollock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-1341","authenticated-orcid":false,"given":"Hannah M.","family":"Cheeseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon R.","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-8057","authenticated-orcid":false,"given":"Hannah L.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-7949","authenticated-orcid":false,"given":"Jennifer","family":"Joypooranachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Shramko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Dispinseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mundsperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Bontjer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana-Marie","family":"Lemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-9539","authenticated-orcid":false,"given":"Sofia","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maniola","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Katinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin J.","family":"Sattentau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Scarlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier W.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-1718","authenticated-orcid":false,"given":"Robin J.","family":"Shattock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105544_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101477","article-title":"Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial","volume":"48","author":"Houser","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib2","doi-asserted-by":"crossref","first-page":"a007278","DOI":"10.1101\/cshperspect.a007278","article-title":"Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1","volume":"1","author":"Kwong","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105544_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines1040497","article-title":"Envelope glycoprotein trimers as HIV-1 vaccine immunogens","volume":"1","author":"Sattentau","year":"2013","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.ebiom.2024.105544_bib4","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.00198-11","article-title":"The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection","volume":"85","author":"Gray","year":"2011","journal-title":"J\u00a0Virol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imr.12481","article-title":"Native-like Env trimers as a platform for HIV-1 vaccine design","volume":"275","author":"Sanders","year":"2017","journal-title":"Immunol Rev"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105544_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105544_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/COH.0000000000000049","article-title":"Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination","volume":"9","author":"Verkoczy","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","article-title":"Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers","volume":"15","author":"Landais","year":"2018","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12516","article-title":"Polyvalent vaccine approaches to combat HIV-1 diversity","volume":"275","author":"Korber","year":"2017","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00738-19","article-title":"Effect of HIV envelope vaccination on the subsequent antibody response to HIV infection","volume":"5","author":"Ditse","year":"2020","journal-title":"mSphere"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105544_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/500215","article-title":"Seroreversion in subjects receiving antiretroviral therapy during acute\/early HIV infection","volume":"42","author":"Hare","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"7446","key":"10.1016\/j.ebiom.2024.105544_bib16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105544_bib17","article-title":"Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions","volume":"4","author":"Caniels","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6623","key":"10.1016\/j.ebiom.2024.105544_bib18","doi-asserted-by":"crossref","first-page":"eadd6502","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"issue":"6470","key":"10.1016\/j.ebiom.2024.105544_bib19","doi-asserted-by":"crossref","first-page":"eaax4380","DOI":"10.1126\/science.aax4380","article-title":"A\u00a0generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.chom.2021.02.002","article-title":"Virus vaccines: proteins prefer prolines","volume":"29","author":"Sanders","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2024.105544_bib21","series-title":"UKRI medical research council: developing healthcare products - experimental medicine","year":"2023"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105544_bib22","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A\u00a0next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105544_bib23","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.celrep.2018.08.051","article-title":"Rational design of DNA-expressed stabilized native-like HIV-1 envelope trimers","volume":"24","author":"Aldon","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib24","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41467-019-10262-5","article-title":"Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence","volume":"10","author":"Sliepen","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.01942-15","article-title":"Chemical cross-linking stabilizes native-like HIV-1 envelope glycoprotein trimer antigens","volume":"90","author":"Schiffner","year":"2016","journal-title":"J\u00a0Virol"},{"issue":"6165","key":"10.1016\/j.ebiom.2024.105544_bib27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105544_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nsmb.2594","article-title":"Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120","volume":"20","author":"Kong","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"6165","key":"10.1016\/j.ebiom.2024.105544_bib29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1126\/science.1245627","article-title":"Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Lyumkis","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41541-023-00696-w","article-title":"Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens","volume":"8","author":"Martin","year":"2023","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib31","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report","volume":"4","author":"Fenyo","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.immuni.2018.07.009","article-title":"Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization","volume":"49","author":"Bianchi","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102476","article-title":"Protocol for analyzing antibody responses to glycoprotein antigens using electron-microscopy-based polyclonal epitope mapping","volume":"4","author":"Turner","year":"2023","journal-title":"STAR Protoc"},{"issue":"3\u20134","key":"10.1016\/j.ebiom.2024.105544_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-3991(99)00043-1","article-title":"Leginon: a system for fully automated acquisition of 1000 electron micrographs a day","volume":"77","author":"Potter","year":"1999","journal-title":"Ultramicroscopy"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsb.2009.01.002","article-title":"Appion: an integrated, database-driven pipeline to facilitate EM image processing","volume":"166","author":"Lander","year":"2009","journal-title":"J\u00a0Struct Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jsb.2009.01.004","article-title":"DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy","volume":"166","author":"Voss","year":"2009","journal-title":"J\u00a0Struct Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsb.2014.03.003","article-title":"Rotationally invariant image representation for viewing direction classification in cryo-EM","volume":"186","author":"Zhao","year":"2014","journal-title":"J\u00a0Struct Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","article-title":"RELION: implementation of a Bayesian approach to cryo-EM structure determination","volume":"180","author":"Scheres","year":"2012","journal-title":"J\u00a0Struct Biol"},{"issue":"13","key":"10.1016\/j.ebiom.2024.105544_bib39","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J\u00a0Comput Chem"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105544_bib40","doi-asserted-by":"crossref","first-page":"e0152038","DOI":"10.1371\/journal.pone.0152038","article-title":"Comparative immunogenicity of HIV-1 gp140 vaccine delivered by parenteral, and mucosal routes in female volunteers; MUCOVAC2, A randomized two Centre study","volume":"11","author":"Cosgrove","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2024.105544_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00149","article-title":"A\u00a0comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein\/adjuvant HIV vaccines in two immunization regimes","volume":"8","author":"Joseph","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2024.105544_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01883","article-title":"Immunoglobulin G1 allotype influences antibody subclass distribution in response to HIV gp140 vaccination","volume":"8","author":"Kratochvil","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105544_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase I randomised clinical trial of an HIV-1CN54, clade C, trimeric envelope vaccine candidate delivered vaginally","volume":"6","author":"Lewis","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A\u00a0guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","article-title":"Army Liposome Formulation (ALF) family of vaccine adjuvants","volume":"19","author":"Alving","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ebiom.2024.105544_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991509","article-title":"Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens","volume":"13","author":"Day","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105544_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"Montefiori","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"31","key":"10.1016\/j.ebiom.2024.105544_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2791","article-title":"Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization","volume":"7","author":"Turner","year":"2021","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41541-022-00576-9","article-title":"Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates","volume":"7","author":"Reiss","year":"2022","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105544_bib50","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat Commun"},{"issue":"31","key":"10.1016\/j.ebiom.2024.105544_bib51","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in\u00a0vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105544_bib52","doi-asserted-by":"crossref","first-page":"e1006987","DOI":"10.1371\/journal.ppat.1006987","article-title":"HIV-specific Fc effector function early in infection predicts the development of\u00a0broadly neutralizing antibodies","volume":"14","author":"Richardson","year":"2018","journal-title":"PLoS Pathog"},{"issue":"30","key":"10.1016\/j.ebiom.2024.105544_bib53","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti\u2013HIV-1 IgG1 antibodies in\u00a0vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105544_bib54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","article-title":"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study","volume":"22","author":"Sridhar","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6452","key":"10.1016\/j.ebiom.2024.105544_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A\u00a0proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105544_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbrc.2009.09.029","article-title":"Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens","volume":"390","author":"Xiao","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105544_bib57","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in\u00a0vivo","volume":"214","author":"Medina-Ram\u00edrez","year":"2017","journal-title":"J\u00a0Exp Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:58:07Z","timestamp":1741924687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424005802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"alternative-id":["S2352396424005802"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105544","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105544"}}